Prostate cancer — all decisions

The appeal seeking readjudication of the previously denied claims for service connection for right lower extremity radiculopathy and vertigo, as well as the requests for readjudication of the previously denied claims for a left shoulder disability, obstructive sleep apnea (OSA), erectile dysfunction (ED), bilateral hearing loss, prostate cancer, bilateral eye pseudophakia, sinus disability, emphysema with left lung nodule, gastroesophageal reflux disease (GERD), skin disability, and posttraumatic stress disorder (PTSD) are dismissed. The request for readjudication of the previously denied claim for service connection for right lower extremity radiculopathy is granted in part as it was fully resolved by a June 2025 rating decision.

The Board denied service connection for prostate cancer as there is no evidence to support a finding that the Veteran's prostate cancer was incurred in or aggravated by his service, including exposure to herbicide agents or other chemical contaminants.

The Board granted service connection for hypertension and prostate cancer, both related to in-service herbicide agent exposure at Fort Chaffe.

The Board remands the issues of entitlement to service connection for a brain tumor and prostate cancer due to insufficient evidence and the need for additional development.

The Board granted an earlier effective date of September 26, 2019, for service connection for hypertension but denied the same for heart disability, DM, and prostate cancer.

The Board granted an effective date of August 10, 2022, for a 100 percent disability rating for prostate cancer and lower urinary tract symptoms, as well as special monthly compensation (SMC) at the housebound rate from the same date.

The Board remands the Veteran's claims for service connection for prostate cancer and an acquired psychiatric disability, to include depression, due to a pre-decisional duty to assist error regarding potential herbicide exposure.

The Board granted a total disability rating based on individual unemployability (TDIU) from August 1, 2022, and also granted special monthly compensation under 38 U.S.C. § 1114(s) and Dependents' Educational Assistance (DEA) benefits beginning the same date.

The Board granted the restoration of a 100 percent rating for prostate cancer effective April 1, 2022, and denied service connection for diabetes mellitus, type II. The claims for service connection for major depressive disorder and peripheral neuropathy of the bilateral lower extremities were remanded.

The Board remands the claims for an earlier effective date for service connection for prostate cancer, ED, and SMC based on loss of use of a creative organ due to lack of substantial compliance with prior remand instructions.

The Board granted service connection for prostate cancer, chronic renal disease, and hypertension due to presumed exposure to contaminated water at Camp Lejeune. Service connection was also granted for depression related to the Veteran's service-connected tinnitus. The claims for service connection for lymphedema, a back condition, gout, a right toe condition, a left ankle condition, diabetes mellitus, bilateral leg clots, bilateral lower extremity neurological conditions, and erectile dysfunction were denied or remanded.

The Board denied earlier effective dates for the grants of service connection for prostate cancer, DM2, and ED as well as the award of SMC under 38 U.S.C. § 1114(k) because no earlier claim was filed within one year of the enactment of the PACT Act.

The Board remands the case to obtain an addendum opinion regarding the etiology of the Veteran's prostate cancer, specifically whether it is caused or aggravated by exposure to contaminated water at Camp Lejeune.

The Board denied the veteran's claims for service connection for prostate cancer, esophageal cancer, an acquired psychiatric disorder, and hypertension as they were not supported by sufficient evidence of a current disability or a nexus to service.

The Board granted an initial 70 percent disability rating for PTSD from October 27, 2011, to October 12, 2019; a 100 percent disability rating for PTSD from October 13, 2019, to August 2, 2021; and a 10 percent disability rating for headaches effective February 10, 2020.

The Board dismissed the veteran's appeal for service connection for heart disability, prostate cancer, diabetes mellitus, type II, and peripheral neuropathy due to a lack of jurisdiction.

The Board granted service connection for prostate cancer, which is presumptively linked to the Veteran's exposure to herbicide agents during his service at Takhli Royal Thai Air Force Base in Thailand.

The Board remands the claims for service connection for Parkinson's disease, prostate cancer, bilateral choroidal melanoma, malignant melanoma of the back, and a respiratory disability due to outstanding evidence and duty-to-assist errors.

The Board granted an initial 40 percent rating for prostate cancer from August 10, 2022, to September 21, 2023, and a 100 percent rating from September 22, 2023, as well as a 100 percent rating for malignant neoplasm of the bones from September 22, 2023.

The Board granted an earlier effective date of August 30, 2022, for the 60 percent rating for prostate cancer and special monthly compensation based on housebound criteria but denied a compensable rating for erectile dysfunction.